Ripretinib
Qinlock (ripretinib) is a small molecule pharmaceutical. Ripretinib was first approved as Qinlock on 2020-05-15. It is used to treat gastrointestinal stromal tumors in the USA. The pharmaceutical is active against mast/stem cell growth factor receptor Kit and platelet-derived growth factor receptor alpha. Qinlock's patents are valid until 2040-08-12 (FDA).
| Trade Name | Qinlock |
|---|---|
| Common Name | Ripretinib |
| Indication | gastrointestinal stromal tumors |
| Drug Class | Retinol derivatives; tyrosine kinase inhibitors |
